Jax DiEugenio

Nemvaleukin alfa produced a disease control rate of 50% in advanced melanoma and RCC.

Early data showing tolerability and improved OS with roginolisib in metastatic uveal melanoma support its ongoing evaluation in the phase 2 OCULE-01 trial.

Ruby Arora, MD, discusses an analysis of SEER data on the declining MCL incidence and disparities that persist in Hispanic and American Indian patients.

Sonam Puri, MD, discusses advances in small cell lung cancer that have expanded treatment options across disease stages.

Tanios S. Bekaii-Saab, MD, discusses evolving frontline and evolving treatment strategies in esophageal cancer, HCC, and NETs.

Extended follow-up showed sintilimab plus anlotinib yielded durable efficacy and tolerability in PD-L1–positive recurrent/metastatic cervical cancer.

Tanios S. Bekaii-Saab, MD, discusses sequencing approaches in metastatic pancreatic cancer and colorectal cancer.

The off-the-shelf therapeutic cancer vaccine plus pembrolizumab improved PFS vs pembrolizumab alone in advanced melanoma.

LV20.19 CAR T therapy produced an 88% CR rate and 100% ORR in relapsed/refractory mantle cell lymphoma.

Tanios S. Bekaii-Saab, MD, highlights how HER2-directed agents, chemoimmunotherapy, and biomarker-driven strategies are expanding options for biliary tract cancers.

ASCO updated their clinical practice guidelines for stage IV NSCLC with or without a driver alteration.

Botensilimab plus balstilimab displayed durable responses in refractory CRC, including in heavily pretreated patient subsets.

Birelentinib received fast track designation from the FDA for relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Pamiparib with paclitaxel, carboplatin, and bevacizumab yields high complete cytoreduction rates, manageable safety in advanced ovarian cancer.

Evelyn Y. Wong, MD, discusses an analysis of a multiracial Asian cohort on the incidence of early‑onset colorectal cancer.

Intravesical mitomycin produced a 24-month DOR rate of 72.2% in recurrent low-grade, intermediate-risk NMIBC.

mRNA‑2416, alone or with durvalumab, was well tolerated and biologically active in advanced solid tumors and ovarian cancer.

Joseph Jacob, MD, MCR, discusses how TAR‑200 could represent a new treatment avenue in BCG‑unresponsive, high-risk NMIBC.

Linda Duska, MD, MPH, discusses final results of KEYNOTE A18 for pembrolizumab plus chemoradiotherapy in high risk, locally advanced cervical cancer.

The Geneva HRD test was predicitive for OS and PFS benefits with olaparib plus bevacizumab in advanced ovarian cancer.

Aditya Bardia, MD, MPH, discusses how Dato‑DXd serves as a new treatment option with a distinct safety profile in HR-positive, HER2‑negative breast cancer.

Joshua Richter, MD, outlines how trispecific antibodies and novel CAR T-cell therapies are shaping the 2025 myeloma landscape and improving patient access.

John Mascarenhas, MD, discusses early findings from the IMproveMF trial combining imetelstat with ruxolitinib in intermediate- to high-risk myelofibrosis.

BB-1701 generated responses with manageable safety in HER2-expressing breast cancer previously treated with an ADC with a topoisomerase I inhibitor.

Gedatolisib triplet and doublet regimens cut the risk of progression by up to 76% vs fulvestrant in HR-positive/HER2-negative advanced breast cancer.

In BRUIN CLL-314, pirtobrutinib met the primary end point of noninferior ORR vs ibrutinib in both the ITT and pretreated subsets of patients with CLL/SLL.

John Mascarenhas, MD, discusses the rationale for evaluating imetelstat in patients with relapsed/refractory myelofibrosis.

Jue Wang, MD, outlines how prolonged androgen suppression may drive prostate cancer evolution.

Sukhmani Padda, MD, discusses ways in which evolving treatment paradigms are tailoring treatment to target atypical EGFR alterations in NSCLC.

The CHMP has issued a positive opinion for the use of vorasidenib in IDH1/IDH2-mutant grade 2 glioma